Compare MESO & PRLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MESO | PRLB |
|---|---|---|
| Founded | 2004 | 1999 |
| Country | Australia | United States |
| Employees | 81 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | 2011 |
| Metric | MESO | PRLB |
|---|---|---|
| Price | $13.93 | $78.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $53.00 |
| AVG Volume (30 Days) | 136.6K | ★ 175.3K |
| Earning Date | 02-26-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | N/A |
| Revenue This Year | $629.74 | $8.56 |
| Revenue Next Year | $30.65 | $6.89 |
| P/E Ratio | ★ N/A | $236.24 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $37.91 |
| 52 Week High | $21.50 | $78.68 |
| Indicator | MESO | PRLB |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 65.26 |
| Support Level | $13.71 | $47.27 |
| Resistance Level | $16.14 | N/A |
| Average True Range (ATR) | 0.47 | 3.00 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 11.08 | 94.44 |
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Proto Labs Inc is an on-demand manufacturer of custom parts for prototyping and short-run production. The company offers developers and engineers quick-turn production services to reduce the time to market. The Lab uses injection molding, computer numerical control machining, and 3-D printing, and sheet metal to manufacture custom parts for its clients. The company services clients' needs for prototype solutions, parts for testing procedures, bridge production capabilities during disruptions in manufacturing processes, limited-quantity requests, and end-of-life production support. Geographically, a majority of the company's revenue is derived from the United States and the rest from Europe.